This Episode Is Sponsored By
Manal Abdelmalek joins the Surfers in a free-flowing discussion of Saturday’s key papers and posters. Much of the talk focused on Lean NASH — what it is some of the new diagnostic analyses and algorithms used to identify patients with or at risk of the disease.
Stephen talked about the extraordinary path that seladelpar took through its Phase 2 NASH trial and Roger revisited an old podcast question: can Patient-Reported Outcomes be part of clinical development planning and, if so, for what kinds of drugs.
Finally, the Surfers welcomed Dr. Nezam Afdhal of Harvard and George Aliphteras of Sonic Incytes in a sponsored extra-sode that is part of the rollout of Velacur, their handheld liver health assessment device. The discussion moved quickly and at the end, all the Surfers were struck powerfully by how dynamically we are learning about this disease.
Roger Green — 1662
ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN A LARGE COHORT OF NASH PATIENTS WITHOUT CIRRHOSIS — ZOBAIR YOUNOSSI
Donna Cryer — 0060
CLINICIAL CHARACTERISTICS USED FOR MACHINE LEARNING IDENTIFICATION OF FAST PROGRESSORS AMONG PATIENTS WITH NASH — JOERN SCHATTENBERG.
Dr. Stephen Harrison — 1710 A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
Manal F. Abdelmalek — 0057
GEMS, A Genetic Metabolic Staging Predicting the Outcome of NAFLD — GRAZIA PENNISI
